--- title: "U.S. stock market midday update: Indaptus Therapeutics down 12.99%, volume increased, sector volatility intensified" type: "News" locale: "en" url: "https://longbridge.com/en/news/294099029.md" description: "Indaptus Therapeutics fell 12.99%; AbbVie rose 3.21%, with a transaction volume of USD 806 million; Amgen rose 4.04%, with a transaction volume of USD 715 million; Gilead Sciences rose 2.55%, with a transaction volume of USD 452 million; Fortress Biotech rose 1.61%, with a market value of USD 123.5 billion" datetime: "2026-07-28T17:53:02.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294099029.md) - [en](https://longbridge.com/en/news/294099029.md) - [zh-HK](https://longbridge.com/zh-HK/news/294099029.md) generator: "portal-rs" --- # U.S. stock market midday update: Indaptus Therapeutics down 12.99%, volume increased, sector volatility intensified **U.S. Stock Market Midday Update** Indaptus Therapeutics, down 12.99%, with increased trading volume and no significant news recently. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. **Stocks with High Trading Volume in the Industry** AbbVie up 3.21%. Based on recent key news: 1. On July 28, AbbVie faced an accelerating risk of Humira revenue erosion. Major pharmacy benefit managers are shifting to biosimilars with interchangeable ratings, threatening established revenue floors and potentially leading to sales losses in the immunology department exceeding expectations. 2. On July 29, AbbVie successfully rebuilt its growth engine. Despite the continued decline in Humira revenue, Skyrizi and Rinvoq generated a combined revenue of $6.6 billion last quarter, helping total immunology revenue grow by 16.4%. AbbVie expects annual sales of these two drugs to approach $32 billion. 3. On July 27, the U.S. Federal Reserve's interest rate decision, preliminary GDP estimates, June PCE data, and employment cost index may affect market expectations and valuations, increasing short-term volatility. Market volatility is rising, with attention on policy signals and technical earnings. Amgen up 4.04%, with increased trading volume. No significant news recently; trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no\_news Gilead Sciences up 2.55%. Based on recent news, 1. On July 28, Gilead Sciences' HIV product sales are expected to reach $20.8 billion by 2025, a 6% year-over-year increase. This growth is primarily driven by its best-selling drug Biktarvy and the newly launched long-acting PrEP injection Yeztugo, enhancing market confidence in the company's future performance and driving the stock price up. 2. On July 28, GlaxoSmithKline's anti-HIV drug Dovato showed efficacy comparable to Gilead Sciences' Biktarvy in studies. Despite increased competition, Biktarvy's market performance remains strong, and investor confidence in Gilead Sciences has not been affected, leading to continued stock price increases. 3. On July 28, market analysts maintained Gilead Sciences' rating at "Moderate Buy," but it was not included in the top recommended stocks list. Nevertheless, Gilead Sciences' robust performance and product line expansion continue to attract investor attention, driving the stock price up. The competition in the HIV drug market is intensifying, but Gilead Sciences is performing steadily. **Stocks with High Market Capitalization in the Industry** Forte Pharmaceuticals up 1.61%. Based on recent key news: 1. On July 28, the pharmaceutical industry showed differentiation, with companies successfully implementing diversification strategies attracting capital, while those facing pipeline failures quickly adjusted valuations. This market dynamic has led to investor interest in Forte Pharmaceuticals' successful diversification strategy, pushing the stock price up by 1.61% Source: Zhitong Finance The pharmaceutical industry is diverging, and the flow of funds is evident ### Related Stocks - [INDP.US](https://longbridge.com/en/quote/INDP.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) - [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md) - [GILD.US](https://longbridge.com/en/quote/GILD.US.md) - [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md) ## Related News & Research - [Indaptus net loss narrows 66% to $1.8 million in Q2 FY26](https://longbridge.com/en/news/295786288.md) - [Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Declines By 64.1%](https://longbridge.com/en/news/295952974.md) - [Insider Traders Lose US$34k As Indaptus Therapeutics Drops](https://longbridge.com/en/news/292064306.md) - [Earnings Scheduled For May 15, 2026](https://longbridge.com/en/news/286557069.md) - [Indaptus Therapeutics Announces Major Leadership and Board Changes](https://longbridge.com/en/news/280372192.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**